News

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.1 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.

Is now the time to buy EXAS? Find out in our full research report (it’s free).

Exact Sciences (EXAS) Q1 CY2025 Highlights:

StockStory’s Take

Exact Sciences began 2025 with notable momentum, attributing Q1 results to improved commercial execution and the launch of new products. Management emphasized that changes made to the sales organization, including territory realignment and expanded field engagement, led to a 30% increase in customer interactions. CEO Kevin Conroy cited early success with the launch of Cologuard Plus and continued growth in the company's rescreen and care gap programs as key drivers of revenue for the quarter.

Looking ahead, management lifted full-year revenue guidance and highlighted the expected impact of new products and operational efficiency initiatives. CFO Aaron Bloomer said the company expects “continued leverage across the P&L,” with gross margin improvements and cost optimization actions underway. Management believes the recent launches and increased provider engagement will support both top-line growth and improving profitability throughout the year.

Key Insights from Management’s Remarks

Management identified several drivers of Q1 performance, including new product launches, enhanced commercial strategy, and operational improvements. Early signs of adoption for Cologuard Plus and increased engagement with healthcare providers contributed meaningfully to results.

Drivers of Future Performance

Management’s outlook for the remainder of 2025 centers on sustained commercial momentum, expanded adoption of new products, and further cost discipline. The company expects these factors to drive high-single-digit to low-double-digit revenue growth and continued margin improvement.

Top Analyst Questions

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace of payer adoption and provider uptake for Cologuard Plus, (2) the volume growth and adherence rates in recurring rescreen and care gap programs, and (3) the upcoming mid-year release of top-line data from the company’s blood-based colon cancer screening trial. Progress in operational efficiency and continued improvement in free cash flow generation will also be important signposts for tracking execution.

Exact Sciences currently trades at a forward P/E ratio of 85.4×. Should you load up, cash out, or stay put? The answer lies in our free research report .

Our Favorite Stocks Right Now

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week . This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today .